The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics
Open accessAbstract
About one fourth of Lewy body disease (LBD) patients show cortical beta-amyloid load, basically a hallmark of Alzheimer disease (AD). Using [11C]PIB-PET, we tested whether LBD patients with beta-amyloid burden differ from those without with respect to demographic, clinical, biochemical and genetic parameters. Thirty-five LBD subjects (9 patients with Lewy body dementia, DLB; 12 demented Parkinson patients, PDD; 14 non-demented PD, PDND) underwent [11C]PIB-PET, and were classified as either PIB(+) or PIB(-) according to cortical PIB uptake. PIB+ and PIB(-) patients were then compared according to demographic, clinical, biochemical and genetic parameters. None of the PDND, but four PDD and four DLB subjects were PIB+. In PIB+ subjects, ApoE4 prevalence was higher, CSF Abeta42 levels were lower and, among demented patients, PIB-binding was associated with a lower MMSE score. Motor symptoms were not associated with PIB binding. Thus, LBD patients with cortical beta-amyloid show characteristics usually observed in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104 · cited 1×
“Increased cortical PIB-uptake has been shown in AD patients and subjects at risk for the development of AD (Engler et al., 2006; Fagan et al., 2006; Kemppainen et al., 2007; Klunk et al., 2004; Mintun et al., 2006; Pike et al., 2007; Price et al., 2005; Rowe et al., 2007).”
BackgroundThe Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
Hansen, L., Salmon, D., Galasko, D., Masliah, E., Katzman, R., DeTeresa, R., Thal, L., Pay, M. M., Hofstetter, R., Klauber, M., et al. (1990) · Neurology · doi:10.1212/wnl.40.1.1 · Cited by 1,068
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 1×
“Increased cortical PIB-uptake has been shown in AD patients and subjects at risk for the development of AD (Engler et al., 2006; Fagan et al., 2006; Kemppainen et al., 2007; Klunk et al., 2004; Mintun et al., 2006; Pike et al., 2007; Price et al., 2005; Rowe et al., 2007).”
BackgroundPike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789
Parkinson disease, dementia, and alzheimer disease: Clinicopathological correlations
Boller, F., Mizutani, T., Roessmann, U., & Gambetti, P. (1980) · Annals of Neurology · doi:10.1002/ana.410070408 · Cited by 451 · cited 1×
“…to post-mortem data, it can be estimated that about one fourth of Lewy body disease patients suffer also from cortical βamyloid burden, with the highest proportion in DLB subjects, followed by PDD subjects (Boller et al., 1980; Braak et al., 2005; Hughes et al., 1993; Jellinger et al., 2003).”
BackgroundImaging amyloid deposition in Lewy body diseases
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Mathis, C. A., Elmaleh, D. R., Shoup, T., Fischman, A. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326146.60732.d6 · Cited by 443
Cited by
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia
Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., Walker, Z., Turkheimer, F. E., & Brooks, D. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.255 · Cited by 274
Cholinergic Dysfunction in Parkinson’s Disease
Müller, M. L. T. M., & Bohnen, N. I. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0377-9 · Cited by 264
Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., Gelsomino, G., Moresco, R. M., & Perani, D. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.07.002 · Cited by 221
“Besides, microglial activation in DLB, might be also associated and influenced by amyloid plaques formation [33].”
BackgroundAmyloid deposition in Parkinson's disease and cognitive impairment: A systematic review
Petrou, M., Dwamena, B. A., Foerster, B. R., MacEachern, M. P., Bohnen, N. I., Müller, M. L., Albin, R. L., & Frey, K. A. (2015) · Movement Disorders · doi:10.1002/mds.26191 · Cited by 208
EFNS task force: the use of neuroimaging in the diagnosis of dementia
Filippi, M., Agosta, F., Barkhof, F., Dubois, B., Fox, N. C., Frisoni, G. B., Jack, C. R., Johannsen, P., Miller, B. L., Nestor, P. J., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03859.x · Cited by 141
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., Rosario, B. L., Lopresti, B. J., Saxton, J. A., Aizenstein, H. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23797 · Cited by 98
Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies
Sarro, L., Senjem, M. L., Lundt, E. S., Przybelski, S. A., Lesnick, T. G., Graff-Radford, J., Boeve, B. F., Lowe, V. J., Ferman, T. J., Knopman, D. S., et al. (2016) · Brain · doi:10.1093/brain/aww193 · Cited by 89
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
“Parkinson’s disease and dementia with Lewy bodies Th e percentage of PIB-positive scans in patients with dementia with Lewy bodies (DLB) has ranged between 30 and 85% in small case series [63-67].”
BackgroundResultClinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Shimada, H., Hirano, S., Sinotoh, H., Ota, T., Tanaka, N., Sato, K., Yamada, M., Fukushi, K., Irie, T., Zhang, M. R., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4338 · Cited by 40
“…could be expected to well discriminate between DLB and AD, because amyloid and tau pathologies observed in DLB are comparable in severity and distribution to those observed in AD (Tsuboi and Dickson, 2005; Gomperts et al., 2008; Maetzler et al., 2009; Shimada et al., 2013; Nedelska et al., 2015).”
BackgroundResultInfluentialVijayaraghavan, S., Maetzler, W., Reimold, M., Lithner, C. U., Liepelt‐Scarfone, I., Berg, D., & Darreh‐Shori, T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.010 · Cited by 24
“previous studies, which showed comparable PiB uptake changes in the brain of patients with AD [30] and patients with LBD [21], and even in older persons without evidence of cognitive dysfunction [31], the cortical regions of interest included the dorsolateral prefrontal, ventrolateral prefrontal, and orbitofrontal reg…”
MethodResultSelf-citation
Metadata
- Authors
- Maetzler, W., Liepelt, I., Reimold, M., Reischl, G., Solbach, C., Becker, C., Schulte, C., Leyhe, T., Keller, S., Melms, A., Gasser, T., & Berg, D.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2009-04
- Volume
- 34
- Issue
- 1
- Pages
- 107-112
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2039700943
- Cited by
- 165
- References
- 11
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.